US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
DE69739673D1
(de)
*
|
1996-11-27 |
2009-12-31 |
Genentech Inc |
Affinitätsreinigung von Polypeptid-Proteinen auf einer Protein A Matrix
|
ES2198913T5
(es)
*
|
1998-05-06 |
2013-11-18 |
Genentech, Inc. |
Purificación de proteínas mediante cromatografía de intercambio iónico
|
US6949245B1
(en)
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
US20030086924A1
(en)
*
|
1999-06-25 |
2003-05-08 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
EP1280923A2
(de)
*
|
2000-04-28 |
2003-02-05 |
Millennium Pharmaceuticals, Inc. |
14094, ein angehörige der menschlichen trypsin-familie, und dessen verwendungen
|
US20020119148A1
(en)
|
2000-09-01 |
2002-08-29 |
Gerritsen Mary E. |
ErbB4 antagonists
|
WO2002098531A1
(en)
|
2001-06-05 |
2002-12-12 |
Genetics Institute, Llc |
Methods for purifying highly anionic proteins
|
AU2002351353A1
(en)
*
|
2001-12-19 |
2003-09-02 |
Genentech, Inc. |
Stabilizing polypeptides which have been exposed to urea
|
ES2322945T5
(es)
*
|
2001-12-21 |
2012-10-17 |
Immunex Corporation |
Métodos para purficación de proteína
|
DK1472275T3
(da)
*
|
2002-02-05 |
2009-04-14 |
Genentech Inc |
Proteinoprensning
|
JP5303092B2
(ja)
|
2002-09-11 |
2013-10-02 |
ジェネンテック, インコーポレイテッド |
タンパク質精製
|
KR101119448B1
(ko)
|
2002-09-11 |
2012-03-15 |
추가이 세이야쿠 가부시키가이샤 |
단백질 정제 방법
|
CN1802388B
(zh)
*
|
2003-05-09 |
2011-01-05 |
杜克大学 |
Cd20特异抗体及使用它们的方法
|
EP3095793B1
(de)
|
2003-07-28 |
2020-03-25 |
Genentech, Inc. |
Verringerung des protein-a-auslaugens während einer affinitätschromatografie
|
US20050065136A1
(en)
*
|
2003-08-13 |
2005-03-24 |
Roby Russell R. |
Methods and compositions for the treatment of infertility using dilute hormone solutions
|
DK2520654T3
(en)
|
2003-08-26 |
2017-05-01 |
Univ Colorado Regents |
Inhibitors of serine protease activity and their use in methods and compositions for the treatment of bacterial infections
|
US20050165222A1
(en)
*
|
2003-10-15 |
2005-07-28 |
Applera Corporation |
Method of reducing leachate from protein a affinity media
|
WO2005045058A2
(en)
*
|
2003-10-27 |
2005-05-19 |
Monogram Biosciences, Inc. |
Detecting human anti-therapeutic antibodies
|
KR101220691B1
(ko)
|
2003-11-05 |
2013-01-14 |
로슈 글리카트 아게 |
증가된 fc 수용체 결합 친화성 및 효과기 기능을 가진cd20 항체
|
WO2005105106A2
(en)
*
|
2004-04-21 |
2005-11-10 |
Roby Russell R |
Hormone treatment of macular degeneration
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
WO2006078307A1
(en)
|
2005-01-21 |
2006-07-27 |
Genentech, Inc. |
Fixed dosing of her antibodies
|
WO2006086730A2
(en)
*
|
2005-02-09 |
2006-08-17 |
Genentech, Inc. |
Inhibiting her2 shedding with matrix metalloprotease antagonists
|
BRPI0606542A8
(pt)
|
2005-02-23 |
2018-03-20 |
Genentech Inc |
métodos para aumentar o tempo de progressão de uma doença (ttp)
|
CA2602951A1
(en)
*
|
2005-03-23 |
2006-09-28 |
Bio-Rad Laboratories, Inc. |
Diverse chemical libraries bound to small particles with paramagnetic properties
|
US20090247421A1
(en)
*
|
2005-03-23 |
2009-10-01 |
Egisto Boschetti |
Diverse chemical libraries bound to small particles with paramagnetic properties
|
JP2006316040A
(ja)
|
2005-05-13 |
2006-11-24 |
Genentech Inc |
Herceptin(登録商標)補助療法
|
PE20070207A1
(es)
*
|
2005-07-22 |
2007-03-09 |
Genentech Inc |
Tratamiento combinado de los tumores que expresan el her
|
DK2500360T3
(en)
*
|
2005-10-31 |
2015-10-26 |
Oncomed Pharm Inc |
Compositions and methods for the diagnosis and treatment of cancer
|
US7723477B2
(en)
*
|
2005-10-31 |
2010-05-25 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
|
US10508144B2
(en)
|
2005-12-20 |
2019-12-17 |
Bristol-Myers Squibb Company |
Carbohydrate content of CTLA4 molecules
|
AR058568A1
(es)
|
2005-12-20 |
2008-02-13 |
Bristol Myers Squibb Co |
Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
|
WO2007081906A2
(en)
*
|
2006-01-06 |
2007-07-19 |
Amgen Inc. |
Purification by column-chromatography using eluants containing organic solvents
|
US8263750B2
(en)
*
|
2006-03-16 |
2012-09-11 |
Amgen Inc. |
Method for purifying a protein using protein-A affinity chromatography using an intermediate wash step
|
FR2902799B1
(fr)
|
2006-06-27 |
2012-10-26 |
Millipore Corp |
Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
|
BRPI0716597A2
(pt)
*
|
2006-09-08 |
2013-10-08 |
Wyeth Corp |
Método para o isolamento de um produto; produto preparado pelo método; método para o isolamento de um anticorpo; método para reduzir a turvação de um eluído compreendendo em produto; e método para reduzir a turvação e impurezas de um eluído compreendendo um produto
|
CN103397065A
(zh)
|
2006-09-13 |
2013-11-20 |
雅培制药有限公司 |
细胞培养改良
|
US8911964B2
(en)
|
2006-09-13 |
2014-12-16 |
Abbvie Inc. |
Fed-batch method of making human anti-TNF-alpha antibody
|
EP2089429B1
(de)
*
|
2006-10-19 |
2014-11-26 |
Janssen Biotech, Inc. |
Verfahren zur herstellung nicht aggregierter antikörper-fc-domänen
|
US8362217B2
(en)
*
|
2006-12-21 |
2013-01-29 |
Emd Millipore Corporation |
Purification of proteins
|
US8569464B2
(en)
*
|
2006-12-21 |
2013-10-29 |
Emd Millipore Corporation |
Purification of proteins
|
WO2008079280A1
(en)
|
2006-12-21 |
2008-07-03 |
Millipore Corporation |
Purification of proteins
|
BRPI0806367A2
(pt)
|
2007-01-22 |
2011-09-06 |
Genentech Inc |
métodos de purificação de anticorpos
|
AU2008208837A1
(en)
*
|
2007-01-26 |
2008-07-31 |
Merck Serono S.A. |
Purification of Fc-TACT fusion proteins using the oilbody technology
|
ES2477497T3
(es)
|
2007-03-02 |
2014-07-17 |
Genentech, Inc. |
Predicción de la respuesta a un inhibidor de la dimerización de HER basado en la expresión de HER3 bajo
|
US9551033B2
(en)
|
2007-06-08 |
2017-01-24 |
Genentech, Inc. |
Gene expression markers of tumor resistance to HER2 inhibitor treatment
|
EP2592156B1
(de)
*
|
2007-06-08 |
2016-04-20 |
Genentech, Inc. |
Genexpressionsmarker für Tumorresistenz gegen Behandlung mit HER2-Inhibitor
|
KR20100061442A
(ko)
|
2007-07-09 |
2010-06-07 |
제넨테크, 인크. |
폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
|
BRPI0817182A2
(pt)
*
|
2007-10-30 |
2015-03-17 |
Genentech Inc |
Método para purificar um anticorpo e composições
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
WO2009151514A1
(en)
*
|
2008-06-11 |
2009-12-17 |
Millipore Corporation |
Stirred tank bioreactor
|
BRPI0812682A2
(pt)
|
2008-06-16 |
2010-06-22 |
Genentech Inc |
tratamento de cáncer de mama metastático
|
TW201438738A
(zh)
|
2008-09-16 |
2014-10-16 |
Genentech Inc |
治療進展型多發性硬化症之方法
|
CN103002911B
(zh)
|
2008-09-26 |
2015-08-26 |
昂考梅德药品有限公司 |
卷曲蛋白结合药剂及其应用
|
EP2346897A2
(de)
|
2008-10-20 |
2011-07-27 |
Abbott Laboratories |
Deaktivierung von viren während der aufreinigung von antikörpern
|
TWI610936B
(zh)
*
|
2008-10-20 |
2018-01-11 |
艾伯維有限公司 |
使用蛋白質a親和性層析進行抗體之分離及純化
|
EP2370561B1
(de)
*
|
2008-12-16 |
2019-08-07 |
EMD Millipore Corporation |
Rührkesselreaktor und verfahren
|
US8846878B1
(en)
*
|
2009-01-23 |
2014-09-30 |
Cubrc Corporation |
Method and device for isolating a protein sample
|
AU2010226453B2
(en)
|
2009-03-20 |
2013-11-21 |
Genentech, Inc. |
Bispecific anti-HER antibodies
|
WO2010136569A1
(en)
|
2009-05-29 |
2010-12-02 |
F. Hoffmann-La Roche Ag |
Modulators for her2 signaling in her2 expressing patients with gastric cancer
|
MX2012000841A
(es)
*
|
2009-07-24 |
2012-02-28 |
Hoffmann La Roche |
Optimizacion de la produccion de anticuerpos.
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
AU2010302662B2
(en)
|
2009-10-01 |
2015-11-26 |
F. Hoffmann-La Roche Ag |
Multistep final filtration
|
WO2011038894A1
(en)
|
2009-10-01 |
2011-04-07 |
F. Hoffmann-La Roche Ag |
Protein a chromatography
|
PL2499165T3
(pl)
|
2009-11-13 |
2017-04-28 |
Grifols Therapeutics Inc. |
Preparaty zawierające czynnik von willenbranda (vwf) oraz sposoby, zestawy i zastosowania z nim powiązane
|
DK2513134T3
(en)
|
2009-12-18 |
2017-12-18 |
Novartis Ag |
Washing solution and process for affinity chromatography
|
TWI535445B
(zh)
|
2010-01-12 |
2016-06-01 |
安可美德藥物股份有限公司 |
Wnt拮抗劑及治療和篩選方法
|
PL2536748T3
(pl)
|
2010-02-18 |
2015-01-30 |
Genentech Inc |
Antagoniści neureguliny i ich zastosowanie w leczeniu nowotworu
|
CA2794674A1
(en)
|
2010-04-01 |
2011-10-06 |
Oncomed Pharmaceuticals, Inc. |
Frizzled-binding agents and uses thereof
|
BR112012028977B1
(pt)
|
2010-05-17 |
2020-05-05 |
Emd Millipore Corp |
método de purificação de biomolécula por meio de polímeros estímulo-responsivos
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
GB201012603D0
(en)
|
2010-07-27 |
2010-09-08 |
Ucb Pharma Sa |
Protein purification
|
US20130245233A1
(en)
|
2010-11-24 |
2013-09-19 |
Ming Lei |
Multispecific Molecules
|
EP2652491B1
(de)
|
2010-12-15 |
2017-11-29 |
Baxalta GmbH |
Eluatsammlung mit leitfähigkeitsgradient
|
JP5766296B2
(ja)
|
2010-12-23 |
2015-08-19 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
|
US9062106B2
(en)
|
2011-04-27 |
2015-06-23 |
Abbvie Inc. |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
EP3628327A1
(de)
|
2011-06-24 |
2020-04-01 |
The Regents of the University of Colorado, A Body Corporate |
Zusammensetzungen, verfahren und verwendung für alpha-1-antitrypsin-fusionsmoleküle
|
JP2014526891A
(ja)
|
2011-08-17 |
2014-10-09 |
ジェネンテック, インコーポレイテッド |
ニューレグリン抗体とその使用
|
HUE044352T2
(hu)
|
2011-10-14 |
2019-10-28 |
Hoffmann La Roche |
Pertuzumab, Trastuzumab, Docetaxel és Carboplatin korai stádiumú mellrák kezelésére
|
WO2013063229A1
(en)
|
2011-10-25 |
2013-05-02 |
The Regents Of The University Of Michigan |
Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
|
LT3257564T
(lt)
*
|
2011-11-02 |
2019-04-10 |
F. Hoffmann-La Roche Ag |
Perkrovos ir eliuentinė chromatografija
|
AU2012346540C1
(en)
|
2011-11-30 |
2019-07-04 |
Genentech, Inc. |
ErbB3 mutations in cancer
|
EP2788500A1
(de)
|
2011-12-09 |
2014-10-15 |
F.Hoffmann-La Roche Ag |
Identifizierung von non-respondern auf her2-inhibitoren
|
KR20140137347A
(ko)
|
2012-01-10 |
2014-12-02 |
더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 |
알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도
|
SG11201406079TA
(en)
|
2012-03-27 |
2014-10-30 |
Genentech Inc |
Diagnosis and treatments relating to her3 inhibitors
|
ES2567091T3
(es)
|
2012-04-05 |
2016-04-19 |
F. Hoffmann-La Roche Ag |
Compuestos de amina para la preparación selectiva de muestras biológicas
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
US9150645B2
(en)
|
2012-04-20 |
2015-10-06 |
Abbvie, Inc. |
Cell culture methods to reduce acidic species
|
WO2013158273A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Methods to modulate c-terminal lysine variant distribution
|
TW201348246A
(zh)
*
|
2012-05-21 |
2013-12-01 |
Abbvie Inc |
利用蛋白質a親和性層析之人類、人類化或嵌合抗體之新穎純化
|
US9249182B2
(en)
|
2012-05-24 |
2016-02-02 |
Abbvie, Inc. |
Purification of antibodies using hydrophobic interaction chromatography
|
SG11201504249XA
(en)
|
2012-09-02 |
2015-07-30 |
Abbvie Inc |
Methods to control protein heterogeneity
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
WO2014043644A1
(en)
|
2012-09-17 |
2014-03-20 |
Alltech Associates, Inc. |
Functionalized particulate support material and methods of making and using the same
|
CA2885263C
(en)
|
2012-09-17 |
2021-11-16 |
W. R. Grace & Co.-Conn. |
Chromatography media and devices
|
CA2887711A1
(en)
|
2012-10-23 |
2014-05-01 |
Oncomed Pharmaceuticals, Inc. |
Methods of treating neuroendocrine tumors using wnt pathway-binding agents
|
CA2889298C
(en)
|
2012-11-30 |
2024-01-02 |
Anton Belousov |
Identification of patients in need of pd-l1 inhibitor cotherapy
|
US9359444B2
(en)
|
2013-02-04 |
2016-06-07 |
Oncomed Pharmaceuticals Inc. |
Methods and monitoring of treatment with a Wnt pathway inhibitor
|
SG10202011130TA
(en)
|
2013-03-08 |
2020-12-30 |
Genzyme Corp |
Continuous purification of therapeutic proteins
|
EP2830651A4
(de)
|
2013-03-12 |
2015-09-02 |
Abbvie Inc |
An humanes tnf-alpha bindende humane antikörper und verfahren zur herstellung davon
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
WO2014159579A1
(en)
|
2013-03-14 |
2014-10-02 |
Abbvie Inc. |
MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
|
US9168300B2
(en)
|
2013-03-14 |
2015-10-27 |
Oncomed Pharmaceuticals, Inc. |
MET-binding agents and uses thereof
|
US9499614B2
(en)
|
2013-03-14 |
2016-11-22 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
|
AR095863A1
(es)
|
2013-04-16 |
2015-11-18 |
Genentech Inc |
Variantes de pertuzumab, su evaluación, método de tratamiento, método de preparación y artículo de fabricación
|
JP6147340B2
(ja)
*
|
2013-05-29 |
2017-06-14 |
Jsr株式会社 |
洗浄用組成物、タンパク質精製方法、及びタンパク質
|
US10519194B2
(en)
*
|
2013-07-12 |
2019-12-31 |
Merck Patent Gmbh |
Removal of fragments from a sample containing a target protein using activated carbon
|
BR112016004437A2
(pt)
|
2013-09-13 |
2017-10-17 |
Genentech Inc |
métodos de imunoteste e de seleção de linhagem de células, anticorpos e kit
|
NZ756749A
(en)
|
2013-09-13 |
2022-05-27 |
Genentech Inc |
Methods and compositions comprising purified recombinant polypeptides
|
EP3052640A2
(de)
|
2013-10-04 |
2016-08-10 |
AbbVie Inc. |
Verwendung von metallionen zur modulation von proteinglykosylierungsprofilen rekombinanter proteine
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
US20150139988A1
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
EP2986307A4
(de)
|
2014-01-03 |
2017-04-12 |
Bio-rad Laboratories, Inc. |
Entfernung von verunreinigungen aus protein-a-eluaten
|
WO2015109068A1
(en)
|
2014-01-16 |
2015-07-23 |
W. R. Grace & Co.-Conn. |
Affinity chromatography media and chromatography devices
|
TWI709569B
(zh)
|
2014-01-17 |
2020-11-11 |
美商健臻公司 |
無菌層析樹脂及其用於製造方法的用途
|
TWI671312B
(zh)
|
2014-01-17 |
2019-09-11 |
美商健臻公司 |
無菌層析法及製法
|
KR20160141857A
(ko)
|
2014-04-25 |
2016-12-09 |
제넨테크, 인크. |
트라스투주맙-mcc-dm1 및 퍼투주맙을 이용하는 초기 유방암의 치료방법
|
EP3137209B1
(de)
|
2014-05-02 |
2022-10-05 |
W.R. Grace & CO. - CONN. |
Funktionalisiertes trägermaterial und verfahren zur herstellung und verwendung eines funktionalisierten trägermaterials
|
US11566082B2
(en)
|
2014-11-17 |
2023-01-31 |
Cytiva Bioprocess R&D Ab |
Mutated immunoglobulin-binding polypeptides
|
SI3302551T1
(sl)
|
2015-05-30 |
2024-10-30 |
F. Hoffmann-La Roche Ag |
Metode zdravljenja predhodno nezdravljenega her2-pozitivnega metastatskega raka dojk
|
BR112017026193B1
(pt)
|
2015-06-05 |
2021-09-14 |
W.R. Grace & Co-Conn |
Adsorventes, método de produção dos adsorventes e uso dos adsorventes
|
WO2017087280A1
(en)
|
2015-11-16 |
2017-05-26 |
Genentech, Inc. |
Methods of treating her2-positive cancer
|
EP3454863A1
(de)
|
2016-05-10 |
2019-03-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Kombinationstherapien zur behandlung von krebs
|
US10889615B2
(en)
|
2016-05-11 |
2021-01-12 |
Cytiva Bioprocess R&D Ab |
Mutated immunoglobulin-binding polypeptides
|
US10703774B2
(en)
|
2016-09-30 |
2020-07-07 |
Ge Healthcare Bioprocess R&D Ab |
Separation method
|
US11708390B2
(en)
|
2016-05-11 |
2023-07-25 |
Cytiva Bioprocess R&D Ab |
Method of storing a separation matrix
|
US10730908B2
(en)
|
2016-05-11 |
2020-08-04 |
Ge Healthcare Bioprocess R&D Ab |
Separation method
|
US10654887B2
(en)
|
2016-05-11 |
2020-05-19 |
Ge Healthcare Bio-Process R&D Ab |
Separation matrix
|
EP3455243B1
(de)
|
2016-05-11 |
2021-03-24 |
Cytiva BioProcess R&D AB |
Trennmatrix
|
JP6987424B2
(ja)
|
2016-05-11 |
2022-01-05 |
サイティバ・バイオプロセス・アールアンドディ・アクチボラグ |
分離マトリックスを洗浄および/または消毒する方法
|
JP7031934B2
(ja)
|
2016-05-11 |
2022-03-08 |
サイティバ・バイオプロセス・アールアンドディ・アクチボラグ |
分離マトリックス
|
WO2018045587A1
(zh)
*
|
2016-09-12 |
2018-03-15 |
广东东阳光药业有限公司 |
一种抗vegf类单克隆抗体的纯化方法
|
CA3040913A1
(en)
|
2016-11-04 |
2018-05-11 |
Genentech, Inc. |
Treatment of her2-positive breast cancer
|
KR102313262B1
(ko)
|
2016-12-28 |
2021-10-14 |
제넨테크, 인크. |
진행성 her2 발현 암의 치료
|
WO2018136412A2
(en)
|
2017-01-17 |
2018-07-26 |
Genentech, Inc. |
Subcutaneous her2 antibody formulations
|
WO2018160654A2
(en)
|
2017-03-02 |
2018-09-07 |
Genentech, Inc. |
Adjuvant treatment of her2-positive breast cancer
|
JP2020517273A
(ja)
|
2017-04-24 |
2020-06-18 |
ジェネンテック, インコーポレイテッド |
膜貫通ドメインまたは膜近傍ドメインにおけるErbB2/Her2突然変異
|
DK3668985T3
(da)
|
2017-08-17 |
2021-09-20 |
Just Evotec Biologics Inc |
Fremgangsmåde til rensning af glycosyleret protein fra værtscellegalectiner og andre urenheder
|
BR112021003420A2
(pt)
|
2018-08-31 |
2021-05-18 |
Genzyme Corporation |
resina cromatográfica estéril e uso da mesma em processos de manufatura
|
KR20220004656A
(ko)
|
2019-04-02 |
2022-01-11 |
본드웰 테크놀로지스 엘피 |
항체의 향상된 정제를 위한 작용화된 ubx 단백질 물질
|